Innovex Promotes Yondelis Cancer Treatment
Innovex and PharmaMar to recruit, train and deploy a specialized oncology sales team in Western Europe to promote Yondelis, PharmaMar's treatment for soft tissue sarcoma. PharmaMar, which holds the marketing authorization, will be responsible for marketing the drug.
Innovex will initially deploy regional unit heads and key account managers in the United Kingdom, Germany, France, Spain and Italy to promote Yondelis. The project will be coordinated across these countries by PharmaMar and an Innovex European project director.
Innovex, a unit of Quintiles Transnational Corp., is the leading global commercial solutions provider to the pharmaceutical, biotech and medical device industries.
"Innovex's proven ability to build and launch sales forces across a multi- country region was a key factor in PharmaMar's selecting us to build its sales network for Yondelis in Western Europe," said Hywel Evans, Global President, Innovex. "This is testament to our ability to rapidly recruit, train and deploy high-performing specialty sales representatives who ensure our customers achieve their sales objectives."
Yondelis was launched Sept. 19 by PharmaMar in the United Kingdom and Germany, following its approval by the European Medicines Agency for use in the treatment of soft tissue sarcoma.
Alfonso Casal, Commercial Director, PharmaMar, said: "This agreement with Innovex means we can optimize the launch of Yondelis across five Western European countries as registration and reimbursement allows. Innovex has demonstrated that they have the ability to recruit high caliber, experienced oncology representatives that understand the marketplace and have the technical expertise required in the oncology market.
"Using Innovex services also gives us both flexibility and scalability in our future sales force deployment."
The project will be overseen by a joint steering committee of representatives from PharmaMar and Innovex.